Feature | October 14, 2011| Dave Fornell

FDA Panel Gives Unanimous Nod to Cook Medical’s Zilver PTX Drug-Eluting Stent

October 14, 2011 – A U.S. Food and Drug Administration (FDA) review panel gave its unanimous recommendation for the market approval of the Zilver PTX stent. It is the first device of its kind on several fronts to go before FDA review. It is the first drug-eluting stent (DES) for peripheral leg vessels, the first self-expanding DES and the first DES that does not use a polymer to load and elute its drug.

All 11 members of the FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee voted Oct. 13 in favor of  Cook Medical's device on the basis of its safety, efficacy and acceptable risk profile. The recommendation is the latest step in the regulatory review process that the company hopes will ultimately lead to FDA approval to sell the Zilver PTX stent in the United States.

“Cook Medical is very pleased that the FDA’s Circulatory System Devices Panel has recognized the merits of Zilver PTX, and we look forward to a final decision on approval to market this device in the U.S. from the FDA in the coming months,” said Rob Lyles, vice president and global leader of Cook Medical’s peripheral intervention unit. “Cook Medical is dedicated to continually innovating and delivering medical devices that improve the quality of patient care worldwide, and we wholeheartedly feel Zilver PTX provides a great example of that patient-focused business philosophy.”

The FDA is not bound by decisions made by its panels, but usually follows their recommendations. Final FDA review will likely take place by the end of the year, or the beginning of 2012.

Following CE mark approval in 2009, Cook Medical’s Zilver PTX DES is now available for sale in 48 countries around the world including the United Kingdom, Germany, France, Brazil, New Zealand and Taiwan.

The stent is seen by many experts as a major step forward in treatment options for patients with peripheral artery disease (PAD) in the superficial femoral artery (SFA). Occlusions in the SFA are difficult to treat and frequently re-occlude.

Zilver PTX is made of nitinol, a shape memory metal alloy that will spring back into its original shape under axial, torsional and bending flexibility. Self-expanding stents are used in the SFA because of the need to torque and compress with the vessel.

The addition of the anti-tissue proliferation drug paclitaxel on the Zilver stent has shown promising results in clinical trials in lowering the usually high restenosis rates of SFA lesions.

Polymers used to load drugs and control drug elution on DES have been implicated as the culprit in late-stent thrombosis sometimes seen in coronary stents. Vendors have been researching ways to eliminate polymers, allowing DES to become a bare metal stent following full drug elution into the vessel wall. The Zilver PTX would be the first DES in the United States not to use polymer, which is seen by many interventional experts as the way of the future.

For more information: www.cookmedical.com

Related Content

TCT 2016, TCT.16, main arena, late breaking trials
Feature | Cath Lab| September 28, 2016
September 28, 2016 — The Cardiovascular Research Foundation (CRF) has announced the 11 late-breaking trials and 16 fi
Bard, Lutonix 014 DCB, drug-coated balloon, six-month endpoint, FDA IDE trial
Technology | Drug-Eluting Balloons| September 26, 2016
C. R. Bard Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE...
Medtronic, In.Pact Admiral drug-coated balloon, trial data, VIVA
News | Drug-Eluting Balloons| September 22, 2016
New data presented at the Vascular Interventional Advances (VIVA) conference demonstrated the durability, consistency...
Shockwave medical, lithoplasty
News | Cath Lab| September 19, 2016
September 19, 2016 — Shockwave Medical announced positive clinical results from the pooled DISRUPT PAD Study, a singl
Sponsored Content | Videos | Peripheral Arterial Disease (PAD)| September 16, 2016
Shockwave Medical’s Lithoplasty System uses ultrasonic waves to treatment calcified plaque in patients with periphera
lithoplasty, lithotripsy for arteries

The Shockwave Medical Lithoplasty system combines a balloon catheter with tiny lithotripsy electrodes that emit pulses to crack and break up calcium in peripheral arteries.

Technology | Peripheral Arterial Disease (PAD)| September 16, 2016
September 16, 2016 — The U.S.
VIVA 2016, late breaking trials, cath lab
Feature | Cath Lab| September 14, 2016
Vascular Interventional Advances (VIVA) 2016 released its list late-breaking research presentations in vascular inter
News | Venous Therapies| September 12, 2016
Veniti Inc. has closed on $25 million in Series D equity financing from Boston Scientific Corp. The funds will allow...
Intact Vascular, TOBA clinical study, one-year results, Tack Endovascular System, Journal of Vascular Surgery
News | Peripheral Arterial Disease (PAD)| August 24, 2016
Intact Vascular Inc. announced that the one-year results from its Tack Optimized Balloon Angioplasty (TOBA) clinical...
News | Peripheral Arterial Disease (PAD)| August 22, 2016
Avinger Inc. recently announced the closing of its previously announced public offering of 9,857,800 shares of Avinger’...
Overlay Init